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Abstract
Background: Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness
analysis of the impact of expanded ART in South Africa.
Methods: We model a best case scenario of 90% annual HIV testing coverage in adults 15–49 years old and four ART
eligibility scenarios: CD4 count ,200 cells/mm3 (current practice), CD4 count ,350, CD4 count ,500, all CD4 levels. 2011–
2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service
and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted
sensitivity analyses.
Results: Expanding ART to CD4 count ,350 cells/mm3 prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV
infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from
109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013.
Compared with the current scenario, expanding to ,500 prevents an additional 585,000 and 3 million new HIV infections
over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10
billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6
billion versus current; other ART scenarios cost $9–194 per DALY averted. If ART reduces transmission by 99%, savings from
all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission
reduce DALYs averted by 26% and savings by 7%.
Conclusion: Increasing the provision of ART to ,350 cells/mm3 may significantly reduce costs while reducing the HIV
burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.
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Introduction
After over 30 years, we still find ourselves struggling to address a
Human Immunodeficiency Virus (HIV) pandemic in which over
30 million people have died [1] [2]. In 2010, estimated 34 million
people were living with HIV with 67% in sub-Saharan Africa [3].
Although approximately 47% of people who need treatment are
getting it, universal access to treatment still remains a dream for
millions [3,4]. By the end of 2010, 6.6 million people were on
antiretroviral treatment (ART), but 7.6 million in need lacked
access, and in 2010 there were an estimated 2.7 million new HIV
infections [3] [4] [5]. Without substantial improvements in
prevention, we are unlikely to meet access targets for life-saving
ART with a projected 47.5 million cumulative HIV infections by
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2031 [6]. Yet stopping the HIV epidemic has proven elusive in
most settings. Behavioral strategies have failed to control
generalized epidemics, despite evidence of good effectiveness for
strategies targeted to high risk situations [7,8]. Biomedical
interventions have been disappointing; one review found that
out of 27 randomized controlled trials including vaccines,
microbicides, and herpes suppression trials, 22 failed to show
efficacy [9,10,11,12]. Positive trials include three for male
circumcision, which in modeling studies shows prevention
potential that is large but insufficient to interrupt the epidemic
[13]. More recently randomized controlled trials on the use of pre-
exposure prophylaxis (PrEP) and ART to prevent HIV transmis-
sion in serodiscordant couples have provided positive results [14]
[15,16,17] and the overall situation has increased interest in the
potential prevention role of ART [18,19].
There is growing scientific evidence that supports the use of
ART for the prevention of HIV transmission. Viral load is the
greatest risk factor for HIV transmission and lowering the viral
load is essential to interrupting transmission [20,21]. Sexual
transmission of HIV-1 is rare among persons with levels of less
than 1500 copies of HIV-1 RNA per milliliter [20,22,23]. ART
dramatically lowers viral load and numerous observational
studies have demonstrated its potential for prevention of HIV
transmission [22,24,25,26]. In Uganda testing and counseling
combined with ART reduced transmission risk by 98% [24]. A
2009 meta-analysis including 11 cohorts (5021 heterosexual
couples) found zero risk of sexual transmission while on ART for
HIV-1 ribonucleic acid below 400 copies and an overall 92%
reduction in transmission risk per person-year for those on ART
versus untreated individuals [27]. A 2010 randomized controlled
study of genital herpes simplex virus (HSV-1) treatment among
HIV-serodiscordant heterosexual couples in Africa found a 92%
reduction in transmission if the HIV-positive partner was on
ART [22]. In May 2011, the HPTN 052 trial comparing
immediate antiretroviral treatment below 550 CD4 mm3 with
delayed treatment for the HIV positive partners in discordant
couples was stopped 4 years early due to compelling evidence
that early treatment reduces HIV transmission in discordant
couples by 96% [14]. The scientific evidence also suggests a
significant community-level impact of ART on HIV transmission
and in British Columbia lower HIV incidence among injecting
drug users is associated with ART use and a decrease in
community plasma HIV-1 RNA concentrations [28]. A 2004
study from Taiwan found a 53% reduction in new HIV cases
associated with free access to ART [29]. A recent San Francisco
study found that the number of new HIV diagnoses fell by 45%
between 2004 and 2008, as average HIV viral load fell by 40%
[30].
Models suggest large potential epidemic effects with expanded
ART. Early theoretical analyses demonstrated that rapid scale-up
of conventional ART approaches could significantly reduce
mortality [31] and have a substantial impact on HIV incidence
[19,32]. Others concluded that expanding access to ART could
foster the proliferation of ARV-resistant strains [33]. A recent
model of the potential impact of ART, using available data and
focusing on a generalized heterosexual HIV epidemic in South
Africa, found that expanding access to ART for everyone at CD4
count ,350 cells/mm3 could have a significant impact on
morbidity, mortality and HIV incidence. Expanding beyond to
all CD4 levels with combined prevention interventions resulted in
a 95% reduction in HIV incidence in 10 years [18]. More recently
the HIV Investment Framework Study Group incorporated the
prevention impact of increased access to ART in their investment
approach for an effective response to HIV/AIDS [34].
There has been an unprecedented investment in confronting the
HIV pandemic–UNAIDS estimated the investment at $13.8
billion in 2008, including half domestic, one third bilateral, one
eighth multilateral, and 5% philanthropic and more recently in
2011 at 16.6 billion [35] [34]. More recently, UNAIDS estimates
that 22 billion annually will be needed to meet targets including
placing 15 million people on ART by 2015 [34] [36]. In 2009 at
the L’Aquila Summit, the G8 confirmed its support for achieving
universal access to HIV prevention, care and treatment [37]. The
global health leadership recently recognized the benefits of earlier
ART. In November 2009 the World Health Organization revised
its ART guidelines to include a CD4 threshold of 350 cells/mm3
[38]. This translated into an estimated 50% increase in the
number of people needing ART, compared to need under the pre-
2009 guideline of 200 CD4 cells/mm3. Given the current shortfall
in ART access, achieving universal access would require a major
effort to reach the millions of people who are immunocompro-
mised but not on treatment. The new guidelines have raised
questions regarding the short-term economic feasibility of
delivering life-saving ART, and the long-term implications for
epidemic trends and costs.
In 2008, South Africa adopted a policy of providing 80% of
HIV-infected individuals with care and support [39] and more
recently has adjusted its ART guidelines to increase earlier access
to treatment [40]. Although some studies have examined financing
the HIV/AIDS response, the net economics of expanding ART,
have not been formally assessed for Southern Africa. [41] [42] [43]
[34,44] [45] [34], except for one recent study comparing CD4
thresholds ,350 cells/mm3 with ,200 cells/mm3 [46]. In the
past, the cost-effectiveness of HIV prevention and of treatment
have been contrasted, to inform the mix of investment in these
apparently distinct activities [47]. This generated considerable
controversy, because of the implication that treatment for sick
individuals could be displaced in favor of more cost-effective
prevention [48]. Expanding access to ART to those earlier in
disease in South Africa offers an analytic and policy opportunity to
align the dual missions of helping sick individuals and lowering the
future societal burden of disease. It also provides insights into the
potential health and economic gains from a ‘front loaded’ HIV
control investment strategy. The analysis presented here assesses
the potential net health system cost, health benefit, and cost-
effectiveness of ART for prevention in South Africa.
Methods
Overview
This economic analysis adds a detailed health system and
costing framework to a previously published [18] and updated
epidemic model (see Information S1 document). We examine four
ART coverage scenarios, defined by the CD4 level at which ART
is offered, up to universal ART. All scenarios include average
annual HIV counseling and testing (HCT). Inputs include
demographic factors, current HIV epidemiology and ART use,
and the utilization and costs of health services off and on of ART.
Outcome measures include new HIV infections, deaths, disability
adjusted life years (DALYs), and cost. Scenarios are compared
incrementally to assess net cost or savings and, for scenarios with a
net cost, cost-effectiveness. The time horizon is 40 years (2011–
2050), with interim 5 year and annual results. Analyses are
repeated for current and enhanced combination HIV prevention.
Sensitivity analyses are performed for all input values. HIV
infections and deaths are reported in nominal values, without
discounting (costs and DALYs are discounted as note below). The
HIV testing and ART interventions are assumed to scale up over
Expanding ART for HIV Treatment and Prevention
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five years. Sensitivity analyses are performed for all input values, to
assess the impact of uncertainty on results. Methods are
summarized below, with additional detail in the Information S1.
ART scenarios
We assume that HIV-infected individuals age 15–49 become
eligible for ART following detection of infection through HIV
counseling and testing (HCT) and CD4 testing (not done in ‘‘All
CD4 scenario’’). HIV progression is followed after age 49. HCT is
assumed in the base case to occur annually, covering 90% of
adults, with equal access by gender and HIV risk level. If the CD4
criteria is met, ART is started after one month; otherwise CD4 is
re-assessed at the next testing cycle.
We assume a well-functioning program and examine ART
coverage scenarios representing a wide range of possible strategies.
The Current practice scenario involves ART initiation at CD4 count
,200 cells/mm3 (at the time of the analysis South Africa had not
switched to ,350 eligibility criteria). In South Africa, the reported
number of people on ART increased from 296,400 in 2006 to
935,800 or 67% of estimated need as of mid 2010. The ART for
CD4 count ,350 cells/mm3 scenario expands coverage to a CD4
initiation level recently recommended in WHO clinical guidelines
[38,49] and partially adopted in South Africa in 2010 [50]. The
ART for CD4 count ,500 cells/mm3 scenario expands coverage to a
CD4 level that typically marks the first HIV-related decline in
immune markers and increased risk of early HIV-related diseases
such as TB [51]. The All CD4 levels scenario involves offering ART
to everyone immediately after diagnosis with HIV irrespective of
CD4 count.
In our model, with randomly distributed annual HIV testing,
the likelihood of identifying infected and antibody positive
individuals is 7.5% per month (90% annual testing target, divided
by 12). Although high acute phase transmission would limit ART’s
effectiveness in blocking transmission our base case is derived from
model calibration to South African surveillance data with
consequent R0 (reproductive rate) and a relatively lower acute
phase risk (see detailed discussion of model calibration in SI
section 6.0). In a sensitivity analysis, we also examine the effect of
30% of transmissions occurring during the acute phase.
Use of ART among those offered is modified by several factors.
We assume that 8% of individuals refuse the offer of ART, and
that drop-out is subsequently 1.5% per annum. These best
practice values are based on monitoring data from the national
program in Malawi (see SI in Granich et al available from authors
on request) [18]. Although retention data from cohorts suggest a
3% annual attrition due to loss to follow up (with a further 2% due
to mortality) [52], we use the best practice figure from the Malawi
program which benefits from a referral system among numerous
clinical sites, thus retaining most individuals who move. We
include mortality (from our clinical progression modeling) and
evolution to 2nd line regimens (3% per year among those
remaining on ART). Individuals on ART survive longer than
those not on ART; thus, over several years the percentage on ART
rises as compared with the proportion initially eligible and
accepting the offer.
Program description
The best practice program that we costed has three major
components: HIV counseling and testing, ART provision, and
human rights and community support. The interventions are
assumed to scale up over five years.
Voluntary HIV counseling and testing (HCT) is provided
through facility-based testing and community campaigns [53,54].
Twenty percent of HCT is facility-based client- and provider-
initiated testing, while community approaches provide access for
the general population (72% of testing) and for marginalized and
institutionalized groups (8%). HCT is scaled up over five years
(from 2011–2016) to 90% and then maintained at that capacity for
annual community and facility-based HIV testing, without
differences in coverage by gender or risk.
We costed the provision of ART and related services
(ambulatory visits and monitoring tests) through existing Depart-
ment of Health infrastructure (facilities and staff) and costs. We did
not estimate a need for added building space, because our analysis
suggests that the overall 25% increase in primary health care visits
(with a shift from illness episodes to routine ART monitoring)
would be balanced by decreased demand on inpatient services. In
the base case, we did not assess the cost of training of personnel for
integrated management of ART. We conducted a sensitivity
analysis on this cost, without assuming any general savings from
improved management (SI, section 5.0). We assumed that all care
would be delivered through the public sector (i.e., people would
use free public ART rather than draw down limited private
coverage).
The human rights and community support has multiple
components. We allow for patient counselors at each HIV testing
site, monitoring in each district, and legal support in each
province, overseen by an independent monitoring organization.
We cost free transport and nutritional support for undernourished
(BMI,18) patients. The training of counselors and other health
care workers includes a human rights and community support
module.
We did not cost other types of HIV prevention, either current or
enhanced, since our goal is to assess the incremental costs and
benefits of expanding ART. For our analysis, all benefits and costs
derive from HIV testing and ART. We assessed how the
prevention context affects ART cost-effectiveness, but not the
cost-effectiveness of prevention, such as behavior change and male
circumcision.
Epidemic model and economic methods
The economic portrayal overlays an epidemic model for South
Africa with detailed data on health system resources and costs.
The epidemic model is a deterministic compartmental model
fitted to the historical HIV epidemic in South Africa [18]. Key
inputs are population size (15 and older), background death and
birth rate, HIV force of infection (a factor that determines
aggregate HIV incidence in susceptibles based on HIV preva-
lence), and rate of progression to death through four equal
duration HIV stages defined by mean CD4 count. Use of ART
reduces the rate of progression by 46%. Averted deaths due to
ART derive entirely from this slowed progression; we do not move
individuals to higher CD4 levels, and we ignore the modest
mortality benefits of ART while at higher CD4 counts. The HIV
testing and ART interventions are assumed to scale up over five
years. Details are available in the original publication and its
supplemental information.18 For this analysis, the model was
updated for new data on rising ART use (see above) and lower
ART effects on force of infection (via transmission efficiency; see
below), and refined to examine varied ART coverage strategies
(detail is provided in the SI).
The programmatic and economic overlay is structured around a
detailed portrayal of geographically-mapped health facilities,
service utilization and costs in South Africa, derived from
Department of Health publications. We portray utilization of
services by facility level and staff type. This is combined with
published research on the utilization of health care services by
stage of HIV disease and as a function of therapy status, and unit
Expanding ART for HIV Treatment and Prevention
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cost data. Detail on unit costs is provided below, and on overall
costing in a technical supplement, on line at [specific URL to be
specified before publication].
Input values
Key input values are presented in Table 1 (with citations) and
below, with added detail in the SI on line.
Epidemic. HIV prevalence of 15.1% in the 15–49 age group
in South Africa comes from UNAIDS reporting. The number on
ART has risen sharply in recent years in South Africa, now
reported at over 900,000 [55]. Mean survival of 11 years without
ART derives from multiple studies, summarized by us previously.
Change in survival due to ART is a 2-fold increase in the base case
levels reaching a survival that is 3.5-times as high as without ART.
The 46% reduction in disease progression for ART derives from
our prior review for ART and added information (see SI). 18 A
study in Uganda provides the basis for the 28% reduction for
cotrimoxazole [56]. The ART-associated reduction in HIV
transmission efficiency (in the model reflected in the force of
infection) derives from a recent review [27] and cohort study [57],
both of which had point estimates of 92%.
Health care. We based ART acceptance rate of 92% and
annual drop-out (excluding deaths) on data from the best
functioning large ART program we could identify, in Malawi.
The rate of change in ART regimens derives from a study in
Uganda. The number of inpatient days while not on ART and the
lower level on ART come from clinical studies in South Africa and
Uganda. These studies found reductions of 84% and 60%
associated with ART, respectively; we use 76% at baseline.
More days and averted days at lower CD4 levels are reported in
the SI. Data on primary health care visits comes from the same
studies, and on reductions in sickness episodes (i.e., opportunistic
infections) from Uganda.
Economic. The unit cost of HIV counseling and testing
($11.10) is derived from testing campaigns in Uganda and Kenya,
adjusted to South African wage levels, and data on facility-based
testing. Costs are in 2009 US$, local prices are converted at the
average exchange rate for 2009 (ZAR 7.407 to 1US$), historic
prices are inflated at 4.9% p.a., future costs are discounted at 3.5%
p.a.
The cost of first line ARV drugs, based on generic 2009
international prices, is $188, and second line is $595, with an
average in the model of $256 for the base case. The most common
first line regimen, representing 60% of actual use, is tenofovir,
lamivudine, and efavirenz ($201); other regiments are reported in
Information S1. Much higher ARV costs are also examined, to
reflect higher prices paid currently in South Africa. The cost of a
level 1 hospital day is $80, based on South Africa-specific data
from WHO CHOICE and consistent with other available data but
potentially less than HIV-specific inpatient care (SI, section 3.0).
ART monitoring costs in the base case includes (usually twice
annually): CD4 ($5), FBC ($7), Creatinine ($7), Chol/TG ($5), and
Table 1. Input values.
Input parameter Baseline value Range Source(s)
Epidemic
HIV prevalence 15.1% [67]
Mean survival HIV infection to death (years) 11 11–14 [18]
Number on ART (mid 2010) 935,828 [82]
Reduction in HIV disease progression rate with ART 0.46 [18]
Reduction in HIV disease progression rate with CTX 0.28 [56]
Reduction in HIV transmission efficiency with ART 0.92 0.85–0.99 [27]
Health care
ART acceptance rate 92% [18]
Number of inpatient days per year, not on ART 7.1 4.5–9.7 [56,61]
Number of inpatient days per year, on ART 1.68 1.6–1.8 [61,62]
Number of visits to PHC per year, not on ART 5.48 [61,83]
Number of visits to PHC per year, on ART 9.6 [61,83]
Morbidity reduction on CTX 0.69 0.84–0.53
Annual HIV counseling and testing 90%(average) – [54]
Costs (US dollars)
HCT (HIV counseling and testing) 11.10 [53,58,84]
First line ARV drugs (per year)* 188 116–751 [58,85]
Second line ARV drugs (per year)* 595 332–1167 [85]
Average hospital day inclusive (level 1/general hospital) 80 70–104 [58]
Average outpatient visit (level 1/general) 28 16–28 [58]
ART monitoring tests new on 1st line therapy 34 34–67 [85–86],
ART monitoring tests new on 2nd line therapy 31 31–158 [85–86],
ART monitoring tests 2nd year on 1st line 24 24–138 [85–86],
ART monitoring tests 2nd year on 2nd line 24 24–264 [85–86],
*Using first and second line costs the modeled average cost for ARVs (USD per year): Baseline: 256 (range 207–674).
doi:10.1371/journal.pone.0030216.t001
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(Glucose ($2); the total is $24–31 per year (prices based on
programmatic experience of authors CB Holmes and C Serenata).
The base case excludes Hepatitis B Surface antigen (HbSag), Viral
Load ($40) and Alanine aminotransferase (ALT, $4), which are
examined in a high-cost monitoring option in the sensitivity
analyses. Local costs are adjusted to 2009 using South African
inflation indices.
Outcome measures
Outcome measures reported for each ART scenario include
process indicators, health events, and standardized outcomes for
cost-effectiveness. The process indicators are the number and
proportion of HIV-infected individuals on ART over time. Health
events include new HIV infections, HIV prevalence, and deaths
while HIV-infected, by year. These outcomes are not discounted.
Standardized outcomes for cost-effectiveness include cost and
disability adjusted life years (DALYs). Cost represents all resources
and associated unit costs for HIV counseling and testing, inpatient
and ambulatory care while HIV-infected, medications including
ART, and laboratory testing to monitor immune status and
toxicities. DALYs are a combined measure of changes in years of
life due to premature mortality, and the disability associated with
illness. By definition, they represent the burden of disease, and
thus are averted by effective interventions. For HIV prevention
and life-prolonging ART, DALYs are almost entirely captured by
the change in mortality; for this analysis we ignore the relatively
modest disability component (about 1.5%), but retain the DALY
nomenclature for comparability. Costs and DALYs are discounted
to 2010 at 3% per year.
Scenarios are compared incrementally to assess net DALYs, net
cost or savings, and, for scenarios with a net cost, cost-
effectiveness. Thus, net DALYs represent the gain in life years
between successive ART scenarios. Net costs (or savings) represent
the gain (or reduction) in total costs due to added costs of
expanded ART and averted costs from averted HIV infections.
With net costs, we calculate the cost per DALY averted. If there
are net savings, the cost-effectiveness ratio is misleading and is not
reported.
Sensitivity analyses
We conducted one-way sensitivity analyses on all variables. In
general, we used ranges that represent values reported in the
scientific literature. For variables that characterize program
functioning (e.g., drop out rates), we used values that represent
well-run HIV testing campaigns and ART programs. That is, we
did not attempt to answer the question, What if the HIV testing or
ART effort was substantially non-functional? For variables that
represent policy choices, such as ARV drug price schedule or
monitoring regimen, we conducted categorical sensitivity analyses,
i.e., option A or option B, but no intermediate value. We also used
a categorical approach to compare current vs. enhanced
prevention, and temporally even vs. acute-phased concentrated
HIV transmission.
We conducted multivariate sensitivity analyses for the 34
continuous variables that affect results by more than 0.5%
(excluding 12 variables below this level). We created a macro
routine in Excel that samples each variable (using a flat statistical
distribution), for 1000 iterations per simulation run. Some input
value ranges are asymmetrical around the base case value, when
we examine only worsening from the best practice assumption in
the base case. Thus, we also present the static result that
corresponds to placing these input values at the mid-point of
their sensitivity analysis ranges. We report the mean and
distribution of findings for these simulations.
Results
Results are presented in Tables 2 and 3 and in figures 1, 2, 3,
4, 5, 6, 7 as indicated. Our baseline findings represent the
potential impact of best practice HIV testing and ART programs.
We also performed sensitivity analyses regarding key assumptions
(see SI).
Table 2. Summary of results, health and cost effects of ART scenarios with current prevention projected over 5 and 40 years
(2011–2050).
Key findings ART scenarios with current prevention projected over 5 and 40 years (2011–2050)
ART Scenario
CD4,200 CD4,350 CD4,500 All CD4
5 yr 40 yr 5 yr 40 yr 5 yr 40 yr 5 yr 40 yr
All CD4 vs
CD4,200
Person years on ART (M) 8 79 12 109 17 131 22 134 134
Change from prior 4.3 30.4 4.7 21.7 4.6 2.8 54.9
New HIV infections (M) 1.6 10.3 1.3 8.7 1.0 6.7 0.6 4.7 5
Change from prior 20.3 21.6 20.3 21.9 20.4 22.1 25.6
Deaths (M) 1.5 12.5 1.3 10.6 1.2 8.7 1.2 7.1 7
Change from prior 20.2 21.9 20.1 21.9 0.0 21.5 25.4
DALYs due to deaths (M) 21 109 18 93 17 78 17 67 67
Change from prior 22.7 215.7 21.0 214.8 20.4 210.9 241.4
Total HIV care costs (M) 14,223 75,339 13,879 71,480 14,056 66,517 14,594 61,505 61,505
Change from prior 2344 23,859 177 24,963 537 25,012 213,833.9
Cost per DALY averted, vs. prior N/A N/A $173 N/A $1,351 N/A N/A
doi:10.1371/journal.pone.0030216.t002
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ART use
Person-years on ART varies from 79 million with ‘‘current’’ to
109 million with ‘‘,350 cells/mm3’’, 131 million with ,500 cells/
mm3, and 134 million with all CD4 levels (about 83% of HIV-
infected), over 40 years (Tables 2 and 3). This pattern reflects
expanded ART initiation at higher CD4 counts which results in
more averted HIV infections and a reduction in future demand.
With enhanced combination prevention (40% lower incidence),
ART use varies from 66 to 110 million person years, reflecting
fewer new HIV infections.
The incidence and prevalence of ART use by year is shown in
Figure 1, for enhanced prevention. The initial prevalence reflects
the CD4 starting point in each scenario. Over time ART use drops
in the more inclusive scenarios, due to averted HIV infections.
The ‘‘all CD4 level’’ scenario has the second lowest ART use by
2050.
Health outcomes
New HIV infections over 5 years decline by 265,000 (17%)
between ‘‘current’’ and ‘‘,350 cells/mm3’’ (Table 2). Over 40
years the decline is 15%, from 8.7 million (‘‘current’’) to 7.3
million (‘‘,350’’) new infections (Table 3). When compared with
the current scenario, expanding from current to ,500 prevents an
additional 585,000 and 3 million new HIV infections over 5 and
40 years, respectively. ‘‘All CD4 levels’’ when compared with
‘‘current’’ scenario prevents 947,000 and 4.7 million over 5 and 40
years, respectively. The comparable values for enhanced preven-
tion are approximately 30% lower in each ART access scenario.
HIV prevalence rises slightly over the first 3–5 years of scaling-up
ART due to decreased mortality, and then drops as a result of
reduced HIV incidence, in proportion to the intensity of ART use.
Differences grow over time for both prevalence and incidence
(Figure 1).
Deaths over 5 years decrease from 1.5 million for ‘‘current’’
ART to 1.3 for ,350 cells/mm3, 1.23 for ,500 cells/mm3 and
1.20 million for ‘‘all CD4 levels’’ under current prevention
(Table 2). Over 40 years, deaths decrease from 12.5 million for
‘‘current’’ ART to 10.6 for #350 cells/mm3, 8.7 for ,500 cells/
mm3 and 7.1 million for ‘‘all CD4 levels’’ under current
prevention, and 10.4, 8.9, 7.4, and 6.5 million respectively for
enhanced prevention (Table 3). Differences between scenarios
start within two years due to the slowing of disease progression,
and expand later with the delayed mortality benefits of averted
HIV infections (Figure 1). Deaths over 5 years decrease from 1.50
million for ‘‘current’’ ART to 1.30 million for ,350 cells/mm3,
1.23 million for ,500 cells/mm3 and 1.20 million for ‘‘all CD4
levels’’ under ‘‘current prevention’’ (Figure 2). The values are
nearly identical for ‘‘enhanced prevention’’, since mortality
prevention benefits in the short term derive from earlier treatment
of already HIV-infected individuals. Although epidemic elimina-
tion (defined as annual HIV incidence rate ,0.001) is not
achieved using the assumption of 92% reduction in transmission
on ART, it can be achieved with various modifications of base case
assumptions including 97% reduction in transmission while on
ART with ‘‘enhanced prevention’’.
Cost-effectiveness: costs and health impact
When compared with the baseline ‘‘current scenario’’, the
cumulative undiscounted cost savings are 7.2, 17.3, and 28.7
billion dollars for ,350, ,500 and all CD4 count scenarios over
the 40 year period (Figure 3). Break even in cumulative costs is
achieved around 2015. Compared with ‘‘current’’, the ‘‘,350
cells/mm3’’ scenario has discounted costs that are lower by $504
million over 5 years, and $3.9 billion over 40 years. With
enhanced prevention, ‘‘,350 cells/mm3’’ reduces costs by $3.3
billion versus ‘‘current’’ over 40 years, ‘‘,500’’ by $3.6 billion
more, and ‘‘all CD4 levels’’ by a final $2.6 billion (Table 2 and 3,
Figure 3).
Annual costs rise for more intensive ART use for several years,
and by around 2017 are below the less intensive ART scenarios,
with differences growing over time (Figure 3). The ‘‘,350 cells/
mm3’’ strategy has only a small and brief annual cost rise over ‘‘All
CD4 levels’’ because of an immediate drop in inpatient utilization
and costs that nearly balances the increase in ART and outpatient
Table 3. Results by ART scenarios with enhanced prevention projected over 5 and 40 years (2011–2050).
Results for ART scenarios with enhanced prevention projected over 5 and 40 years (2011–2050)
ART Scenario
CD4,200 CD4,350 CD4,500 All CD4
5 yr 40 yr 5 yr 40 yr 5 yr 40 yr 5 yr 40 yr
All CD4 vs
CD4,200
Person years on ART (millions) 8 66 12 89 17 105 21 110 110
Change from prior scenario 4.2 23.5 4.6 16.1 4.4 4.4 44.0
New HIV infections (millions) 1.2 7.6 1.0 6.2 0.8 4.7 0.5 3.3 3
Change from prior scenario 20.2 21.4 20.2 21.5 20.3 21.4 24.3
Deaths (millions) 10.1 10.4 1.5 8.9 1.3 7.4 1.2 6.5 6
Change from prior scenario 28.6 21.6 20.2 21.4 20.1 21.0 24.0
DALYs due to deaths (millions, NPV) 21 95 18 82 17 71 17 63 63
Change from prior scenario 22.7 213.0 21.0 211.2 20.4 27.2 231.3
Total HIV care costs (millions, NPV) 14,119 65,120 13,785 61,821 13,969 58,196 14,503 55,559 55,559
Change from prior scenario 2333.7 23,298.6 183.9 23,624.6 533.7 22,637.0 29,560.2
Cost per DALY averted, vs. prior scenario N/A N/A $182 N/A $1,381 N/A N/A
Notes: ART scenarios refer to the CD4 level at which ART is offered. Enhanced prevention assumes a 40% reduction in HIV incidence before expansion of ART. See text
for detail.
doi:10.1371/journal.pone.0030216.t003
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costs. Differences in cumulative costs grow steadily over time (data
not shown). The average annual costs by category reflect the
relatively small proportion of costs due to ARV drugs (Figure 4)
and the shift in type of expenditures reflects the addition of ARV
drugs and a drop in hospital costs (Figure 5). Although the greatest
differences in spending are reflected when contrasting immediate
and current scenarios, savings are accrued for all scenarios when
contrasted with the current approach (Figure 6).
DALYs decline from 109 to 67 million, discounted, with an 11
to 16 million difference between each ART scenario. Enhancing
prevention (40% lower HIV incidence) reduces DALYs averted by
expanding ART by 27% and cost differences by 37% (Tables 2
and 3, Figure 7). With enhanced prevention, these differences drop
by about one quarter (Tables 2 and 3, Figure 7). The
proportionate cost difference across scenarios is smaller than for
DALYs because ART only improves health (through treatment
and prevention) but has competing effects on costs (increased in
the short term, decreased in the long term).
Sensitivity analyses
Varying most input values over specified uncertainty ranges
preserves the qualitative findings of net savings and substantial
averted DALYs (see SI section 5).
One-way. A higher annual drop-out rate on ART (3% or 5%,
instead of the 1.5% base case value from the Malawi national
program) results in a decrease from 41 million DALYs averted
over 40 years in the base case to 33–37 million DALYs averted for
the higher drop out rates. The decrease is consistent across the
Figure 1. Key epidemic indicators by ART scenario, over time, enhanced prevention scenario to 2050. This figure presents key epidemic
results. The adult population is the denominator. ‘‘Blue’’ is all CD4 levels, ‘‘Yellow’’ is ,500/mm3, ‘‘Pink’’ is ,350/mm3, and ‘‘Black’’ is current ,200/
mm3. The ‘‘Incidence rate’’ graphs show that the rate of new HIV infections drops most sharply with higher ART use due to more inclusive CD4
criteria. The ‘‘Prevalence Rate’’ graphs show a similar but more gradual decline in HIV prevalence with more ART, and also show that differences in
ART use in the short term converge over time due to averted infections The ‘‘Annual death rate’’ graph highlights the benefit of expanded ART on
death rates.
doi:10.1371/journal.pone.0030216.g001
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CD4 levels, since more time in ART always decreases DALYs.
The cost reduction drops from $14 billion in the base case to $13
billion at 5% drop-out. The effect varies by CD4 level, due to
competing influences on costs as individuals exit ART. The initial
refusal rate (4 to 12% range) makes a difference of ,500,000
DALYs averted over 40 years, mainly due to repeated ART offers
to refusers (not in table).
Life expectancy off ART has opposite effects on DALYs and
costs: an increase to 14 years decreases DALYs averted but
increases cost savings with ART. The increase in life expectancy
from ART (to 3.5 fold from 2 fold) increases both DALYs averted
and savings.
If ART reduces transmission by 99% instead of 92%, net
savings from all CD4 level versus current reach $17.5 billion. If
ART reduces transmission by only 85%, the savings are $12.6
billion. The scenarios differ in terms of DALYs only modestly for
two reasons: many DALYs averted derive from the current
benefits of treatment not prevention, and a difference of 1% vs.
15% in residual transmission risk among individuals on ART
yields a smaller relative difference when adjusted for the
proportion not on ART (84% in ‘‘all CD4’’ and greater in other
scenarios).
Higher 2009 South Africa ART costs results in all CD4 level
ART saving $0.6 billion versus current ART. However, intermediate
scenarios have net higher costs of $3.05 and $0.14 billion versus
less ART-intensive scenarios, with cost-effectiveness of $9–194 per
DALY averted. Using broadly higher costs based on South Africa
data (higher ART and monitoring costs, longer inpatient stays and
higher daily costs, compared to our baseline values) results in
higher net savings than the base case.
Figure 2. Lives saved by CD4 treatment threshold compared to current CD4,200 baseline. Graph shows lives saved by CD4 treatment
threshold compared to current CD4,200 baseline with the ,350 scenario portrayed in ‘‘pink’’, ,500 in ‘‘yellow’’ and all CD4 in ‘‘blue’’. Lives saved
increase with earlier access to ART.
doi:10.1371/journal.pone.0030216.g002
Figure 3. Annual cost by scenario compared to current prevention scenario baseline, 2010–2050. This figure shows the annual cost by
ART scenario compared to the projected baseline of ,200 current scenario. Totals represent cumulative cost savings over 2010–2050 time period.
Cost neutral time points cluster around 2015. Discounted savings over 40 years are 3.9, 8.8, and 13.8 billion for ,350, ,500, and all CD4 cells,
respectively.
doi:10.1371/journal.pone.0030216.g003
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The rate of ART regimen change is inversely proportional to net
savings, with no effect on DALYs in our model. An unfavorable case
that combines full South Africa costs with low testing coverage, high
ART refusals, and high drop outs leads to 42% fewer DALYs
averted and 30% lower net savings, with a cost of $59 per DALY for
the increment from CD4 count .500 cells/mm3 to ‘‘All CD4
levels’’. Use of cotrimoxazole in the CD4 level one higher than
designated for initiating ART results in 3–15% reduction in DALYs
averted and small changes in net savings that vary according to the
comparison. Testing every 3 years instead of annually results in 14%
more DALYs overall (i.e., higher disease burden), and 5–47%
smaller differences between ART scenarios. This analysis conser-
vatively assumes CD4 testing on the same frequency.
The reduction in inpatient days (from 7.1 days per year off ART
to 1.7 on ART, on average) is unrelated to DALYs, and directly
related to savings. Inpatient day cost has a similar effect.
Figure 4. Average annual costs by category with breakdown of human rights and community support components. The pie
represents the annual costs based on a CD4,350 scenario without additional prevention averaged over 40 years. Care includes hospital and primary
health care (excluding nutrition and human rights), which have their own slices in the pie. Outreach represents the costs of the community-based
campaign excluding human rights and community support costs. ART represents ARV costs, aboratory and clinic visits are included in Care category.
The other categories are self-explanatory and further details can be found in the Information S1 document.
doi:10.1371/journal.pone.0030216.g004
Figure 5. Undiscounted expenditure over 40 years by type of cost and scenario. These histograms show how projected expenditures over
40 years vary as a function of the ART scenario. As ART intensity rises, overall spending drops, with a modest rise in ARV drug costs and a larger drop
in hospital costs.
doi:10.1371/journal.pone.0030216.g005
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We examined implementing training in integrated management
of HIV, as recommended by WHO (not in table). A 5-year
program training 50% of PHC staff, followed by annual turnover
at 10%, would cost $156 million in the first 5 years and $115
million per five year period thereafter, for a discounted cost over
40 years of $569 million, or about 7% of net savings. We ignore
likely compensatory savings from decentralization to less expensive
facilities and better organization of care.
Multivariate. Some input value ranges are asymmetrical
around the base case value, when we examine only worsening
from the best practice assumption in the base case (See SI Section
5). Thus, as a comparison with the multivariate simulations, Table
Figure 6. Difference in spending by ART scenario, 2010–2050 (discounted to 2010). This bar chart represents the difference in spending
between different ART scenarios over 40 years (discounted to 2010). The ART scenario comparison is indicated on the horizontal axis, and the cost
difference on the vertical axis (in millions). Negative numbers indicate fewer costs with more use of ART. Findings under current prevention impact
are indicated in blue, and under enhanced prevention in maroon. The differences between scenarios are greater for current than enhanced
prevention.
doi:10.1371/journal.pone.0030216.g006
Figure 7. Difference in DALYs by ART scenario, 2010–2050 (discounted to 2010). This bar chart represents the difference in Disability
Adjusted Life Years (DALYs) between different ART scenarios, over 40 years (discounted to 2010). The ART scenario comparison is indicated in the
horizontal axis label. The DALY difference is indicated on the vertical axis (in thousands). Negative numbers indicate fewer DALYs with more use of
ART, representing lower disease burden. Findings with current prevention are indicated in blue, and with enhanced prevention in maroon. The
differences between ART scenarios are greater under current prevention impact than assumed enhanced prevention impact.
doi:10.1371/journal.pone.0030216.g007
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4 in the Information S1 document contains a static result that
corresponds to placing these input values at the mid-point of their
sensitivity analysis ranges. DALYs averted are 38,000, compared
with 41,000 in the base case. Net savings are $10.5 billion,
compared with $13.8 billion in the base case.
The ‘‘even stages’’ analysis assumes that HIV risk is not
concentrated in the acute phase, similar to our base case
assumption. The mean change in DALYs and costs is similar to
the static case described immediately above. The distribution of
findings is shown in the SI Section 5. Net savings are achieved in
99% of simulations. With 30% of HIV transmission in the 3
month acute phase, DALYs averted drop by 26% to 31 million
and the net savings drop by 7% to $12.8 billion.
Discussion
As part of a well-run ART program, our projections suggest that
a ‘front loaded’ investment into expanding ART for people living
with HIV with a CD4 count ,350 cells/mm3 could yield results
almost immediately. Expanded access could reduce new HIV
infections by an estimated 265,000 over five years and 1.4 million
over 40 years. Over the near term, the investment strategy could
save lives by reducing estimated deaths by 200,000 with a
projected savings of $504 million over 5 years. Over 40 years, it
could reduce estimated deaths by 2.9 million, disability adjusted
life years by 15.7 million, and an estimated reduction in costs of
$3.9 billion. These projections support WHO’s recent recommen-
dations to start ART earlier for those with #350 CD4 cells/mm3
and South Africa’s recent decision to expand access [38].
There is increasing evidence that earlier treatment may be
advantageous for both prevention and clinical care [14]. However,
starting earlier also comes with potential risks including potential
adverse effects and difficulties accessing second line treatment.
Modeling the health and economic impact provides an opportu-
nity to examine a number of interventions and scenarios.
Expanding to CD4 count ,500 cells/mm3could further reduce
estimated deaths by 1.9 million and disability adjusted life years by
14.8 million over 40 years. This expanded access strategy could
decrease costs by an estimated $100 million over five years and
$5.0 billion over 40 years. Although we based our assumptions on
a well-run program, the result of net savings is robust to
uncertainty in most input assumptions, such as transmission
suppression, reduction in inpatient days, and use of pre-ART
cotrimoxazole prophylaxis. However, savings depend substantially
on South Africa using lower cost international sourcing for anti-
retroviral drugs. Most people in South Africa are starting ART
very late in the course of disease, however, extending ART access
to people earlier after HIV infection has potential additional
economic and epidemiologic impact. According to our projections,
adopting a policy of ART for all CD4 levels could result in a
further estimated decline of 3.3 million infections, 3.5 million
deaths, 25.7 million DALYs, and $10 billion over 40 years, as
compared with CD4 count ,350 cells/mm3. The expansion to all
CD4 levels could achieve cost breakeven by 2022 (within 10 years)
versus ‘‘current’’. In the context of enhanced prevention (40%
lower incidence), ART expansion could still substantially reduce
HIV health burden and lower costs, and could be an essential
contributor to epidemic elimination by the standard of annual
HIV incidence ,0.001.
The substantial projected net savings reflect the anticipated
epidemic impact of ART, as well as economic and epidemic
conditions in South Africa. Over multiple years and decades, the
assumed 92% reduction in HIV transmission among those on
ART sharply reduces new infections and associated medical costs.
These savings are substantial per person due to the relatively high
cost of medical care in South Africa, as compared with most of
sub-Saharan Africa [58]. Indeed, we found that an expensive
intervention like ART yields savings even in the short term (5
years), based on slowed progression to more expensive disease
stages and data suggesting that individuals with CD4 counts at
least as high as 500 have serious HIV-related morbidity and
mortality and associated inpatient care, which ART reduces by
60–80% [59,60,61,62]. The large overall magnitude of savings
reflects the large scale of the HIV epidemic in South Africa. Past
cost-effectiveness analyses of ART in Africa, including our own,
omitted the indirect, dynamic epidemic effects of ART through
reduced HIV transmission and were conducted in settings with
lower medical care costs. Thus, they found substantial net costs
and relatively high cost-effectiveness: $597 per DALY averted in
Uganda, including prevention effects but only in immediate
partners; and $620 per DALY averted in Cote d’Ivoire [59,63]. An
analysis of future resource needs for AIDS in low- and middle-
income countries predicted 20% savings with enhanced targeted
prevention and 44% higher costs with broad program scale-up,
but did not consider the HIV infections and costs averted with
expanded ART [41]. A cost-effectiveness analysis of ART
expansion in Vancouver, Canada, using a willingness-to-pay
approach, estimated a net benefit of US$ 900 million over 30 years
[64].
Our analysis links within one framework three key issues in
global HIV: low but growing knowledge of HIV status, falling
ART costs, and evidence for ART suppression of HIV
transmission [4] [34] [65,66]. According to the WHO, between
2005 and 2008, the median percent of persons living with HIV
who reported receiving HIV test results increased from 15% to
39% [67]. Still, in some settings the need for increased HIV testing
is stark; the Kenya AIDS Indicator Study found that in 2007 only
17% of those testing HIV-positive knew of their status [68].
Second, the cost of ART is falling, in PEPFAR to the range of
$400–500 per person year, including about 39% for the ARV
drugs; there remain issues in fully understanding costs and their
determinants [69] [70]. Finally, quantitative evidence of suppres-
sion of HIV transmission during ART is converging on an over
90% reduction, although this remains to be confirmed during field
implementation in larger-scale programs and over a longer-term
than the recent cohort studies and HPTN 052 clinical trial which
reported a 96% reduction [14] [22,27]. Importantly, initial
evidence suggests that viral load suppression by ART is
accompanied by lower risk behaviour, in South Africa [71] and
elsewhere [72]. Other recent analyses have costed and projected a
significant combined prevention impact of expanding ART for the
majority of people living with HIV with a CD4 cell count ,350
[34]. In Botswana, patterns in sexual behaviour have remained
relatively stable since 2000 and the country scaled up access to
treatment from less than 5% in 2000 to over 80% which it has
maintained since 2009. The annual number of new HIV infections
has declined by over two thirds since the late nineties and data
suggests that the number of new HIV infections in Botswana is
30% to 50% lower today than it would have been in the absence of
antiretroviral therapy [3]. Recent studies show that treatment can
be up to 96% effective in preventing HIV transmission among
couples [14]. Taken together, these factors suggest large need and
opportunity for expanded testing and earlier treatment.
Our study has important limitations. We do not explicitly
portray anti-retroviral resistance. Resistance has been proposed as
major drawback of expanded access to ART in modeled analyses
[33]. However, accumulating empirical evidence suggests that
these concerns are not borne out with ART in community
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practice, where little clinical relevant resistance has been
documented (e.g., Vancouver [73]), perhaps due to the recent
advances in ART that increase adherence and decrease resistance
[74]. We do capture the effect of expected modest resistance
through the shift to (more expensive) second line ART. We assume
no exhaustion of ARV regimen options. More generally, our
model has only one mechanism whereby earlier ART initiation
can increase mortality: ART drop-out rate. HPTN 052 demon-
strated a 40% reduction in health related events for those started
immediately below 550 CD4 count and current clinical trials such
as START and TEMPRANO will provide additional data on
clinical outcomes with early ART initiation [14]. Our epidemi-
ologic model is not risk, age- or gender-structured, so we could not
examine targeted strategies. We are adapting the model for this
purpose. We assume excellent ART program operation, based on
the example of Malawi, one of the poorest countries in the world.
Although we explore the implications of weaker programming,
such as higher drop-out rates but do not examine what would
happen in the face of lower levels of access to HIV testing and
counseling and/or linkage to care and treatment. However, our
analysis should be considered to represent the potential gains from
the expanded use of ART in programs with optimal programmatic
achievements that can be found in some of the best programs
serving individuals under current treatment guidelines (lower CD4
levels). Given the recent recognition of the short and long-term
mortality benefits of ART even at high CD4, we think this
perspective is reasonable. Furthermore, we believe that a ‘‘best
practices’’ approach is consonant with increasing emphasis on
program performance in global health. Donors are investing more
cautiously, driven by global economic problems and tighter
budgets. Thus, programs must show good results in order to
continue receiving broad support; ineffective programs must be
improved or their funding redirected to programs with strong
performance. Ultimately, the objective of donor initiatives should
be to ensure that money is spent wisely and leads efficiently to
better health for the world’s poor. A best practices approach sets
the bar high, as we think is appropriate as programs increasingly
focus on expanding access to earlier HIV testing, counseling and
ART with accompanying monitoring and evaluation of imple-
mentation.
Decisions around the cost of end-of life care are important and
we assumed that end-of-life care is less expensive with ART, i.e.,
that there is no final intensive utilization comparable to that
observed with no ART. Although, this assumption has important
policy and cost implications, for our analysis of early ART
initiation, it has little consequence: individuals with CD4 count
,200 cells/mm3 are offered ART in all scenarios. However, if the
assumption leads to understating lifetime costs of HIV care, then
we underestimate the savings due to averted HIV infections. Our
results are conservative in that we also omitted several important
types of health benefits and care savings: preventing tuberculosis in
index patients and contacts [75], benefits to family members [60],
and benefits above CD4 count of 500 cells/mm3 [62]. Addition-
ally, by using annual CD4 testing for HIV-infected not yet on
ART, we likely delay ART initiation compared with every 6
month testing often used in operating programs. We also exclude
the broad economic and social benefits of reduced HIV infections
which are likely to be very substantial, but uncertain in magnitude
and beyond our scope [76].
For the cost analysis, we assume that the savings due to averted
inpatient care can be captured in financial savings or in expanded
services for other health conditions. This assumption, though
potentially difficult to operationalize in the short term due to fixed
and under-utilized health care resources, is the same as in other
cost-effectiveness and net cost analyses. Our findings apply only to
South Africa, whereas the economics of expanded ART may differ
in settings with different cost structure or epidemiology [76]. For
example, due to South Africa’s relatively high cost of inpatient
care, the cost savings from reduced hospitalizations for persons
with HIV are larger than in most other African countries, while
the cost of ARV drugs is comparable. Lower HIV prevalence may
lead to a higher relative cost burden from HCT, though this
distinction largely disappears after the first round of testing.
Recognizing this geographical limitation, we plan to use our model
to assess other settings with a set of revised input values.
Other ‘ART for prevention’ evaluations in recent years have
been less optimistic than this one. As noted above, a theoretical
analysis for San Francisco found a substantial risk of epidemics of
resistant ARV strains with scale-up [33]; empirical evidence to
date fails to confirm these risks [73]. Another modeling analysis
found that a ‘‘test-and-treat’’ strategy can substantially reduce
HIV transmission, ‘‘broadly confirm[ing] the main findings’’ from
our prior model [77]. However, the analysis also found that the
intervention works less well in populations with highly heteroge-
nous risk segmentation (i.e., high risk core groups and non-
sustaining risk in low risk remainder), or if coverage is less than
50%. It found that for the cost-efficiency ratio [reduction in HIV
incidence] divided by [cost for ART and HCT], 80% coverage
was optimal along with a testing interval of 1–5 years depending
on the epidemic scenario. Importantly, the analysis did not
incorporate ART drop-out and offsetting savings in medical care
as in this paper. Greater ART drop-out rates substantially
decrease the expected scale of health benefits, with less
pronounced effects on net savings. Some projections place more
emphasis on data from cohort studies which suggest a substantial
concentration of HIV transmission in the acute phase. Although
the surveillance and other evidence from South Africa demon-
strates a lower contribution, accounting for a larger proportion of
transmission in the acute phase would only lower DALYs averted
by one-quarter and savings by 7%. Perhaps most importantly, the
92–96% reduction in HIV transmission during ART as found in
recent cohort studies and a clinical trials, and the patient retention
and adherence rates taken from Malawi’s best-practice program,
remain to confirmed empirically in the context of other large-scale
programs, sustained over a longer-term as needed in South Africa.
WHO recommends expanding access to ART for #350 cells/
mm3 and recognizes that expanding access to ART within a
human rights framework is paramount: without community
engagement and support expanding access to #350 cells/mm3
will likely be impossible. It is critical that there is community
engagement in the planning and implementation of the program,
that there is no coercion to be HIV tested or take ART, and that
there is adequate support for individuals with questions and
concerns. Contrary to many other similar studies, we included the
cost of ensuring many components of a strong human rights
framework [78]. A related issue is the motivation for individuals
with early HIV disease to accept ART, given the low risk of HIV-
related death. How early to start ART remains controversial,
however, despite the growing scientific evidence and potential for
individual [62], public health and economic benefits, several
reservations have been raised regarding the desirability and
feasibility of expansion to the CD4 count ,500 cells/mm3 and
‘‘all CD4 levels’’ [33]. The 2009 WHO international expert
committee, after a rigorous review of the scientific evidence base,
feasibility, and cost considerations, reached consensus for starting
ART at ,350 cells/mm3 [38].
On the practical side, a major concern has been the logistical
challenge of expanding care, which seems at first glance would
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disrupt the health system. We agree that expanding ART to CD4
count #350 cells/mm3 levels will be, in many settings, a difficult
undertaking; even the resource needs to maintain current efforts in
the intermediate term are substantial [79]. However, we found
that for South Africa, in cost terms, intervening earlier is predicted
to pay for itself within 4 to 12 years (with gains accumulating over
time as infections are averted), so expanding ART is initially less a
jump in resources than a shift from inpatient to ambulatory care.
The costing assumes more use of lay providers and task shifting to
manage the increase in routine management of care, leaving the
existing clinical staff to deliver clinical care. Regarding HIV
control strategy, some experts argue that effective, efficient
traditional HIV prevention should be scaled up. We agree, and
point in particular to interventions in high risk groups such as sex
workers, male circumcision, and HIV testing and counseling,
especially in discordant couples [80,81]. Indeed, our model found
that epidemic elimination is most likely with the combination of
these strategies and ART expanded to all CD4 levels. Finally, we
recognize the link between program performance and impact. In
order to yield broad epidemic benefits, an ART for prevention
strategy must achieve high HIV testing levels, high acceptance of
ART, and high retention and adherence within ART, especially
on first line regimens. Thus effective implementation must
promote, monitor, and achieve high performance in these areas.
Our analysis offers several insights into the economics and
impact of ART for prevention in South Africa. First, moving from
current ART practice to WHO’s recommended starting rule of
CD4 count #350 cells/mm3 is likely to save substantial lives and
money, within a few years and more over time. South Africa
recently adopted this CD4 level as the guideline for pregnant
women and TB patients and we hope accumulating data will allow
us to refine our analyses to include these groups. Second, extension
of ART to CD4 count ,500 cells/mm3 and all CD4 levels is likely
to save even more lives and money, albeit requiring large ‘front
loaded’ investments that may be challenging to marshal. Third,
these favorable findings owe much to the potent combination of
high averted inpatient costs, low antiretroviral drug costs, and
many HIV infections averted. Finally, the most profound epidemic
abatement can occur only in the context of enhanced traditional
prevention. We believe that economic analysis is helpful to
understand the broad implications of a complex intervention like
ART for prevention. For example, only through integration of
diverse data on health care utilization and costs were we able to
identify the favorable economics of expanded ART in South
Africa. From a resource mobilization perspective, our findings
suggest that through a ‘front loaded’ investment strategy the costs
of responding to HIV epidemic could reach a level requiring only
minimal external support. Similar economic modeling will be
valuable in this and other geographic settings, to increase the
robustness and subtlety of our understanding of ART for
prevention. The models should also allow modification of
parameter values to explore policy options under consideration
by health officials. In conclusion, we believe that accumulated
evidence and analyses support the implementation of phased
program implementation to assess the capacity of health systems to
deliver and sustain earlier ART, including HIV testing and
counseling, ART uptake, retention and adherence, and its
community-level impact on HIV transmission and costs.
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